These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17707686)

  • 21. Crucial components of Mycobacterium type II fatty acid biosynthesis (Fas-II) and their inhibitors.
    Duan X; Xiang X; Xie J
    FEMS Microbiol Lett; 2014 Nov; 360(2):87-99. PubMed ID: 25227413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the fungal fatty acid synthase type I multienzyme complex.
    Johansson P; Wiltschi B; Kumari P; Kessler B; Vonrhein C; Vonck J; Oesterhelt D; Grininger M
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12803-8. PubMed ID: 18725634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel FabH inhibitors: an updated article literature review (July 2012 to June 2013).
    Song H; Ao GZ; Li HQ
    Expert Opin Ther Pat; 2014 Jan; 24(1):19-27. PubMed ID: 24083428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery.
    Bermingham A; Derrick JP
    Bioessays; 2002 Jul; 24(7):637-48. PubMed ID: 12111724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Product diversity and regulation of type II fatty acid synthases.
    Lu YJ; Zhang YM; Rock CO
    Biochem Cell Biol; 2004 Feb; 82(1):145-55. PubMed ID: 15052334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty Acid synthesis as a target for antimalarial drug discovery.
    Lu JZ; Lee PJ; Waters NC; Prigge ST
    Comb Chem High Throughput Screen; 2005 Feb; 8(1):15-26. PubMed ID: 15720194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A view of development of new antibacterial agents with novel targets].
    Watanabe Y; Minami S
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():248-53. PubMed ID: 12717979
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel targets for the future development of antibacterial agents.
    McDevitt D; Payne DJ; Holmes DJ; Rosenberg M
    Symp Ser Soc Appl Microbiol; 2002; (31):28S-34S. PubMed ID: 12481826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing.
    Singh SB; Phillips JW; Wang J
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):160-6. PubMed ID: 17436551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platensimycin is a selective FabF inhibitor with potent antibiotic properties.
    Wang J; Soisson SM; Young K; Shoop W; Kodali S; Galgoci A; Painter R; Parthasarathy G; Tang YS; Cummings R; Ha S; Dorso K; Motyl M; Jayasuriya H; Ondeyka J; Herath K; Zhang C; Hernandez L; Allocco J; Basilio A; Tormo JR; Genilloud O; Vicente F; Pelaez F; Colwell L; Lee SH; Michael B; Felcetto T; Gill C; Silver LL; Hermes JD; Bartizal K; Barrett J; Schmatz D; Becker JW; Cully D; Singh SB
    Nature; 2006 May; 441(7091):358-61. PubMed ID: 16710421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current understanding of fatty acid biosynthesis and the acyl carrier protein.
    Chan DI; Vogel HJ
    Biochem J; 2010 Aug; 430(1):1-19. PubMed ID: 20662770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure and conformational variability of the mycobacterium tuberculosis fatty acid synthase multienzyme complex.
    Ciccarelli L; Connell SR; Enderle M; Mills DJ; Vonck J; Grininger M
    Structure; 2013 Jul; 21(7):1251-7. PubMed ID: 23746808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway.
    Wong KK; Pompliano DL
    Adv Exp Med Biol; 1998; 456():197-217. PubMed ID: 10549370
    [No Abstract]   [Full Text] [Related]  

  • 34. Forty years of bacterial fatty acid synthesis.
    Rock CO; Jackowski S
    Biochem Biophys Res Commun; 2002 Apr; 292(5):1155-66. PubMed ID: 11969206
    [No Abstract]   [Full Text] [Related]  

  • 35. Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF.
    Hrast M; Turk S; Sosič I; Knez D; Randall CP; Barreteau H; Contreras-Martel C; Dessen A; O'Neill AJ; Mengin-Lecreulx D; Blanot D; Gobec S
    Eur J Med Chem; 2013 Aug; 66():32-45. PubMed ID: 23786712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.
    Wu M; Singh SB; Wang J; Chung CC; Salituro G; Karanam BV; Lee SH; Powles M; Ellsworth KP; Lassman ME; Miller C; Myers RW; Tota MR; Zhang BB; Li C
    Proc Natl Acad Sci U S A; 2011 Mar; 108(13):5378-83. PubMed ID: 21389266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase III (mtFabH) assay: principles and method.
    Sachdeva S; Reynolds KA
    Methods Mol Med; 2008; 142():205-13. PubMed ID: 18437316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids.
    Zheng CJ; Yoo JS; Lee TG; Cho HY; Kim YH; Kim WG
    FEBS Lett; 2005 Sep; 579(23):5157-62. PubMed ID: 16146629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
    Pohlmann J; Lampe T; Shimada M; Nell PG; Pernerstorfer J; Svenstrup N; Brunner NA; Schiffer G; Freiberg C
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1189-92. PubMed ID: 15686939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway.
    Schneider T; Sahl HG
    Int J Med Microbiol; 2010 Feb; 300(2-3):161-9. PubMed ID: 20005776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.